218600-44-3 | 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$20.00	$14.00
5mg	98%	in stock	$43.00	$30.00
25mg	98%	in stock	$108.00	$76.00
100mg	98%	in stock	$286.00	$200.00
250mg	98%	in stock	$409.00	$286.00
1g	98%	in stock	$1,088.00	$761.00

Description

• Catalog Number: AF32117
• Chemical Name: 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid
• CAS Number: 218600-44-3
• Molecular Formula: C31H41NO4
• Molecular Weight: 491.6615
• MDL Number: MFCD07772296
• SMILES: N#CC1=C[C@@]2(C)C(C(C1=O)(C)C)CC[C@@]1(C2=CC(=O)[C@H]2[C@@]1(C)CC[C@@]1([C@@H]2CC(C)(C)CC1)C(=O)O)C
• NSC Number: 711193

Computed Properties

• Complexity: 1200
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 7
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 1
• XLogP3: 6.4

Literature

• Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway.

  Toxicology 20140406

• Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO.

  PloS one 20140101

• Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents.

  Journal of medicinal chemistry 20120524

• Antioxidants in kidney diseases: the impact of bardoxolone methyl.

  International journal of nephrology 20120101

• Synthesis and biological evaluation of 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4-ethynylimidazole. A novel and highly potent anti-inflammatory and cytoprotective agent.

  Bioorganic & medicinal chemistry letters 20110415

• Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.

  Journal of medicinal chemistry 20110324

• 2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-inflammatory and cytoprotective agent.

  Bioorganic & medicinal chemistry letters 20100401

• CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha.

  Blood 20071115

• Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents.

  Journal of medicinal chemistry 20070419

• Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A.

  Bioorganic & medicinal chemistry letters 20061215

• Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action.

  Bioorganic & medicinal chemistry letters 20050502

• Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress.

  Proceedings of the National Academy of Sciences of the United States of America 20050322

• Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets.

  Journal of medicinal chemistry 20040923

• Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: a novel class of highly active inhibitors of nitric oxide production in mouse macrophages.

  Journal of medicinal chemistry 20021024

• A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production.

  Bioorganic & medicinal chemistry letters 20020408

• A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma.

  Molecular endocrinology (Baltimore, Md.) 20001001